Skip to Main Content

Author Details

Francesca Demichelis
University of Trento
1969
180
66
Emma Lundberg (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
37989010The role of life cycle thinking-based methodologies in the development of waste management plans.Waste Manag2024
37989010The role of life cycle thinking-based methodologies in the development of waste management plans.Waste Manag2024
36653909MIMESIS: minimal DNA-methylation signatures to quantify and classify tumor signals in tissue and cell-free DNA samples.Brief Bioinform2023
38046436Integrating extracellular vesicle and circulating cell-free DNA analysis using a single plasma aliquot improves the detection of HER2 positivity in breast cancer patients.J Extracell Biol2023
36653909MIMESIS: minimal DNA-methylation signatures to quantify and classify tumor signals in tissue and cell-free DNA samples.Brief Bioinform2023
37072390Bladder cancer organoids as a functional system to model different disease stages and therapy response.Nat Commun2023
38046436Integrating extracellular vesicle and circulating cell-free DNA analysis using a single plasma aliquot improves the detection of HER2 positivity in breast cancer patients.J Extracell Biol2023
37072390Bladder cancer organoids as a functional system to model different disease stages and therapy response.Nat Commun2023
34656688Circulating RNAs in prostate cancer patients.Cancer Lett2022
35259458ETS-related gene (ERG) undermines genome stability in mouse prostate progenitors via Gsk3β dependent Nkx3.1 degradation.Cancer Lett2022
34731645Allele-specific genomic data elucidate the role of somatic gain and copy-number neutral loss of heterozygosity in cancer.Cell Syst2022
35267426Past, Current, and Future Strategies to Target ERG Fusion-Positive Prostate Cancer.Cancers (Basel)2022
34656688Circulating RNAs in prostate cancer patients.Cancer Lett2022
34605002Plasma tumor DNA is associated with increased risk of venous thromboembolism in metastatic castration-resistant cancer patients.Int J Cancer2022
35220606Comparative genomics of primary prostate cancer and paired metastases: insights from 12 molecular case studies.J Pathol2022
35220606Comparative genomics of primary prostate cancer and paired metastases: insights from 12 molecular case studies.J Pathol2022
35267426Past, Current, and Future Strategies to Target ERG Fusion-Positive Prostate Cancer.Cancers (Basel)2022
35259458ETS-related gene (ERG) undermines genome stability in mouse prostate progenitors via Gsk3β dependent Nkx3.1 degradation.Cancer Lett2022
34731645Allele-specific genomic data elucidate the role of somatic gain and copy-number neutral loss of heterozygosity in cancer.Cell Syst2022
34605002Plasma tumor DNA is associated with increased risk of venous thromboembolism in metastatic castration-resistant cancer patients.Int J Cancer2022
33318707Publisher Correction: Mutation-selection balance and compensatory mechanisms in tumour evolution.Nat Rev Genet2021
34111024Therapy considerations in neuroendocrine prostate cancer: what next?Endocr Relat Cancer2021
33998599Tumor subtype defines distinct pathways of molecular and clinical progression in primary prostate cancer.J Clin Invest2021
33318707Publisher Correction: Mutation-selection balance and compensatory mechanisms in tumour evolution.Nat Rev Genet2021
33257848Mutation-selection balance and compensatory mechanisms in tumour evolution.Nat Rev Genet2021
33293234Erratum to 'Core Biopsies from Prostate Cancer Patients in Active Surveillance Protocols Harbor PTEN and MYC Alterations'[European Urology Oncology 2 (2019) 277-285].Eur Urol Oncol2021
34728774Charting differentially methylated regions in cancer with Rocker-meth.Commun Biol2021
34429855Fast mutual exclusivity algorithm nominates potential synthetic lethal gene pairs through brute force matrix product computations.Comput Struct Biotechnol J2021
34429855Fast mutual exclusivity algorithm nominates potential synthetic lethal gene pairs through brute force matrix product computations.Comput Struct Biotechnol J2021
34728774Charting differentially methylated regions in cancer with Rocker-meth.Commun Biol2021
34111024Therapy considerations in neuroendocrine prostate cancer: what next?Endocr Relat Cancer2021
33998599Tumor subtype defines distinct pathways of molecular and clinical progression in primary prostate cancer.J Clin Invest2021
33257848Mutation-selection balance and compensatory mechanisms in tumour evolution.Nat Rev Genet2021
33293234Erratum to 'Core Biopsies from Prostate Cancer Patients in Active Surveillance Protocols Harbor PTEN and MYC Alterations'[European Urology Oncology 2 (2019) 277-285].Eur Urol Oncol2021
32332823Integrative multiplatform molecular profiling of benign prostatic hyperplasia identifies distinct subtypes.Nat Commun2020
32332823Integrative multiplatform molecular profiling of benign prostatic hyperplasia identifies distinct subtypes.Nat Commun2020
32091413Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer.J Clin Invest2020
31922552ABEMUS: platform-specific and data-informed detection of somatic SNVs in cfDNA.Bioinformatics2020
32149736Genome-wide plasma DNA methylation features of metastatic prostate cancer.J Clin Invest2020
33144576Role of specialized composition of SWI/SNF complexes in prostate cancer lineage plasticity.Nat Commun2020
33033248Two distinct immunopathological profiles in autopsy lungs of COVID-19.Nat Commun2020
33015524Systematic Assessment of Tumor Purity and Its Clinical Implications.JCO Precis Oncol2020
32671985Inherited variant in NFκB-1 promoter is associated with increased risk of IBD in an Algerian population and modulates SOX9 binding.Cancer Rep (Hoboken)2020
32669676Plasma tumour DNA as an early indicator of treatment response in metastatic castration-resistant prostate cancer.Br J Cancer2020
31922552ABEMUS: platform-specific and data-informed detection of somatic SNVs in cfDNA.Bioinformatics2020
32091413Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer.J Clin Invest2020
33144576Role of specialized composition of SWI/SNF complexes in prostate cancer lineage plasticity.Nat Commun2020
33033248Two distinct immunopathological profiles in autopsy lungs of COVID-19.Nat Commun2020
33015524Systematic Assessment of Tumor Purity and Its Clinical Implications.JCO Precis Oncol2020
32671985Inherited variant in NFκB-1 promoter is associated with increased risk of IBD in an Algerian population and modulates SOX9 binding.Cancer Rep (Hoboken)2020
  • 1 - 50 of 360

Recommended Authors

Takafumi N Yamaguchi
University of California los angeles
Career Start Year 2015
Number of shared co-authors 19
Wei Yuan
The Institute for Cancer Research
Career Start Year 2015
Number of shared co-authors 42
Daniel Vod??k
Institute for Cancer Research, Oslo University Hospital
Career Start Year 2014
Number of shared co-authors 13
Matti Annala
University of British Columbia
Career Start Year 2011
Number of shared co-authors 45
Geoff Macintyre
CRUK Cambridge Institute, University of Cambridge
Career Start Year 2009
Number of shared co-authors 2
David A Quigley
University of California-San Francisco
Career Start Year 2008
Number of shared co-authors 44
Ritu Roy
University of California San Francisco.
Career Start Year 2007
Number of shared co-authors 8
Matti Nykter
Prostate Cancer Research Center, Tampere University and Tays Cancer Center
Career Start Year 2006
Number of shared co-authors 38
Nicola Waddell
QIMR Berghofer Medical Research Institute
Career Start Year 2006
Number of shared co-authors 8
David C Wedge
Manchester Cancer Research Centre, University of Manchester
Career Start Year 2006
Number of shared co-authors 14
Jamie K Teer
H. Lee Moffitt Cancer Center and Research Institute
Career Start Year 2005
Number of shared co-authors 3
Michael C Haffner
Fred Hutchinson Cancer Center
Career Start Year 2005
Number of shared co-authors 64
Albrecht Stenzinger
Institute of Pathology, University Hospital Heidelberg
Career Start Year 2005
Number of shared co-authors 15
Jochen K Lennerz
Massachusetts General Hospital/Harvard Medical School
Career Start Year 2004
Number of shared co-authors 6
Jianmin Wang
Roswell Park Comprehensive Cancer Center
Career Start Year 2003
Number of shared co-authors 6
Daniel S Brewer
University of Washington, USA Institute for Stem Cell and Regenerative Medicine
Career Start Year 2003
Number of shared co-authors 23
Olivier Harismendy
University of California
Career Start Year 2003
Number of shared co-authors 5
Obi L Griffith
Washington University
Career Start Year 2003
Number of shared co-authors 11
Luciano G Martelotto
Monash University
Career Start Year 2000
Number of shared co-authors 8
Srinivasan Yegnasubramanian
Johns Hopkins University School of Medicine
Career Start Year 1999
Number of shared co-authors 33
Paul T Spellman
Oregon Health & Science University Hospital.
Career Start Year 1998
Number of shared co-authors 24
John V Pearson
QIMR Berghofer Medical Research Institute
Career Start Year 1996
Number of shared co-authors 13
Wim Van Criekinge
Ghent University
Career Start Year 1995
Number of shared co-authors 8
Anamaria A Camargo
Hospital Sirio-Libanes
Career Start Year 1994
Number of shared co-authors 2
Adam B Olshen
12224University of California san francisco
Career Start Year 1993
Number of shared co-authors 18
Yong-Jie Lu
Barts Cancer Institute, Queen Mary University of London
Career Start Year 1993
Number of shared co-authors 19
Kathleen E Houlahan
University of California los angeles
Career Start Year 1991
Number of shared co-authors 14
Luigi Marchionni
Weill-Cornell School of Medicine
Career Start Year 1989
Number of shared co-authors 27
Eivind Hovig
Center for Bioinformatics, University of Oslo
Career Start Year 1987
Number of shared co-authors 7
Olli Kallioniemi
Karolinska Institute
Career Start Year 1984
Number of shared co-authors 18

Collaborators

Mark A Rubin
University of Bern
Co-authored papers 94
Andrea Sboner
Institute for Computational Biomedicine
Co-authored papers 45
Himisha Beltran
Dana-Farber Cancer Institute
Co-authored papers 35
Juan Miguel Mosquera
Caryl and Israel Englander Institute for Precision Medicine
Co-authored papers 30
Alessandro Romanel
University of Trento
Co-authored papers 29
Davide Prandi
University of Trento
Co-authored papers 25
Arul M Chinnaiyan
University of Michigan Medical School.
Co-authored papers 24
Olivier Elemento
Meyer Cancer Center
Co-authored papers 21
David S Rickman
Meyer Cancer Center
Co-authored papers 16
Christopher E Barbieri
Weill Cornell Medical College
Co-authored papers 16
Levi A Garraway
Broad Institute of Harvard and MIT
Co-authored papers 15
Philip W Kantoff
Memorial Sloan Kettering Cancer Center
Co-authored papers 14
Brian D Robinson
Sandra and Edward Meyer Cancer Center
Co-authored papers 13
Ashutosh K Tewari
Co-authored papers 12
Theresa Y MacDonald
Caryl and Israel Englander Institute for Precision Medicine
Co-authored papers 12
Robert Kim
University of California
Co-authored papers 11
Dolores Di Vizio
Cedars-Sinai Medical Center
Co-authored papers 11
David M Nanus
Sandra and Edward Meyer Cancer Center
Co-authored papers 11
Scott T Tagawa
Meyer Cancer Center, Weill Cornell Medicine-NewYork Presbyterian Hospital
Co-authored papers 11
Scott A Tomlins
Rogel Cancer Center, University of Michigan Medical School ann arbor
Co-authored papers 11
Kyung Park
New York University Langone Health
Co-authored papers 11
Mark Gerstein
Yale University
Co-authored papers 11
Gerhardt Attard
The Institute of Cancer Research
Co-authored papers 10
Naoki Kitabayashi
Co-authored papers 10
Johann S de Bono
The Institute for Cancer Research
Co-authored papers 10
Joanna Cyrta
Paris Sciences Lettres University PSL, Institut CURIE
Co-authored papers 9
Eliezer M Van Allen
Dana-Farber Cancer Institute
Co-authored papers 9
Michael R Freeman
Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center
Co-authored papers 8
Samprit Banerjee
Weill Cornell Medical College, Cornell University
Co-authored papers 8
Charles L Sawyers
Memorial Sloan Kettering Cancer Center
Co-authored papers 8
Release 1.2